Related Experiment Video
Updated: Jan 26, 2026

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
Published on: December 26, 2014
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies
Carl W Noble1, Sapna S Gangaputra2, Ian A Thompson3
1Department of Ophthalmology, George Washington University , Washington DC, USA.
Purpose:
To report the clinical features, severity, and management of ocular immune-related adverse events (irAEs) in the setting of immune checkpoint inhibitor therapy for metastatic malignancies.
Methods:
Retrospective chart review at three tertiary ophthalmology clinics. Electronic medical records were reviewed between 2000 and 2017 for patients with new ocular symptoms while undergoing checkpoint inhibition therapy.
Results:
Eleven patients were identified. Ocular irAEs ranged from keratoconjunctivitis sicca to Vogt-Koyanagi-Harada-like findings. Average timing of irAEs from starting checkpoint inhibitor therapy was 15.7 weeks. Ocular inflammation was successfully controlled with corticosteroids in most cases, however three patients discontinue treatment as a result of ocular inflammation with decreased visual acuity, two discontinued due to progression of metastatic disease, and one discontinued due to severe systemic irAEs.
Conclusion:
We found a wide spectrum of ocular irAEs associated with immune checkpoint inhibitors. In most cases, ocular AEs did not limit ongoing cancer treatment.
Insights
Immune checkpoint inhibitors can cause various ocular immune-related adverse events (irAEs), ranging from dry eye to severe inflammation. Most cases were managed with corticosteroids, allowing patients to continue cancer treatment.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment.
- Ocular immune-related adverse events (irAEs) are a potential complication of ICI therapy.
- Understanding the spectrum and management of ocular irAEs is crucial for patient care.
Purpose of the Study:
- To characterize the clinical features, severity, and management strategies for ocular irAEs.
- To investigate the impact of ocular irAEs on ongoing cancer therapy.
Main Methods:
- Retrospective chart review of patients treated with ICIs between 2000 and 2017.
- Analysis of clinical data from three tertiary ophthalmology clinics.
- Identification of patients with new-onset ocular symptoms during ICI therapy.
Main Results:
- Eleven patients with ocular irAEs were identified.
- Ocular irAEs presented with a wide range of conditions, including keratoconjunctivitis sicca and Vogt-Koyanagi-Harada-like findings.
- Average onset of ocular irAEs was 15.7 weeks after starting ICI therapy.
- Corticosteroids effectively managed ocular inflammation in most patients.
- Three patients discontinued treatment due to ocular irAEs impacting visual acuity.
Conclusions:
- Immune checkpoint inhibitors are associated with a diverse spectrum of ocular irAEs.
- Ocular irAEs generally do not necessitate discontinuation of cancer treatment.
- Prompt diagnosis and management of ocular irAEs are important for preserving vision and enabling continued oncologic care.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
What is the Immune System?
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

